Nicola Fossati

List of Publications by Year in Descending Order

201 papers	7,177 citations	39 h-index	80 g-index
215 ext. papers	9,994 ext. citations	6.3 avg, IF	5.71 L-index

#	Paper	IF	Citations
201	Clinical Case Debate: Immunotherapy Versus Alternative Therapies in the Neoadjuvant and Adjuvant Setting of Localized, High-Risk Prostate Cancer **2022**, 145-160		
200	The Value of Multiparametric Magnetic Resonance Imaging Sequences to Assist in the Decision Making of Muscle-invasive Bladder Cancer. *European Urology Oncology*, **2021**, 4, 829-833	6.7	8
199	Assessing the Clinical Value of Positive Multiparametric Magnetic Resonance Imaging in Young Men with a Suspicion of Prostate Cancer. *European Urology Oncology*, **2021**, 4, 594-600	6.7	5
198	Positive Predictive Value of Prostate Imaging Reporting and Data System Version 2 for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis. *European Urology Oncology*, **2021**, 4, 697-713	6.7	20
197	Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy. *European Urology Focus*, **2021**, 7, 1092-1099	5.1	1
196	Metastatic hormone-sensitive prostate cancer: local treatment strategies. *World Journal of Urology*, **2021**, 1	4	0
195	Prostate-specific Membrane Antigen Imaging in Clinical Guidelines: European Association of Urology, National Comprehensive Cancer Network, and Beyond. *European Urology Focus*, **2021**, 7, 245-249	5.1	2
194	Age and gleason score upgrading between prostate biopsy and radical prostatectomy: Is this still true in the multiparametric resonance imaging era?. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 784.e1-784.e9	2.8	0
193	Management of Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy: A Systematic Review of the Literature. *European Urology Oncology*, **2021**, 4, 150-169	6.7	9
192	Optimizing prostate-targeted biopsy schemes in men with multiple mpMRI visible lesions: should we target all suspicious areas? Results of a two institution series. *Prostate Cancer and Prostatic Diseases*, **2021**, 24, 1137-1142	6.2	0
191	Patient- and Tumour-related Prognostic Factors for Urinary Incontinence After Radical Prostatectomy for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis. *European Urology Focus*, **2021**,	5.1	6
190	Re: Sophie Knipper, Luigi Ascalone, Benjamin Ziegler, et al. Salvage Surgery in Patients with Local Recurrence After Radical Prostatectomy. Eur Urol 2021;79:537-44: Surgical Treatment of Local Recurrence Following Radical Prostatectomy: Reality or Illusion?. *European Urology*, **2021**, 79, e132-e133	10.2	
189	Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate Cancer. Letter. *Journal of Urology*, **2021**, 205, 1839	2.5	
188	A Systematic Review of Focal Ablative Therapy for Clinically Localised Prostate Cancer in Comparison with Standard Management Options: Limitations of the Available Evidence and Recommendations for Clinical Practice and Further Research. *European Urology Oncology*, **2021**, 4, 405-423	6.7	6
187	Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer. *Journal of the National Cancer Institute*, **2021**, 113, 48-53	9.7	15
186	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. *European Urology*, **2021**, 79, 243-262	10.2	382
185	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. *European Urology*, **2021**, 79, 263-282	10.2	186

184	Re: Histological comparison between predictive value of preoperative 3-T multiparametric MRI and Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer. *BJU International*, **2021**, 127, 746	5.6	
183	[18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 235.e15-235.e21	2.8	3
182	Defining Clinically Meaningful Positive Surgical Margins in Patients Undergoing Radical Prostatectomy for Localised Prostate Cancer. *European Urology Oncology*, **2021**, 4, 42-48	6.7	15
181	Defining the Most Informative Intermediate Clinical Endpoints for Patients Treated with Salvage Radiotherapy for Prostate-specific Antigen Rise After Radical Prostatectomy. *European Urology Oncology*, **2021**, 4, 301-304	6.7	1
180	Re: Long-Term Outcomes of Active Surveillance for Prostate Cancer: The Memorial Sloan Kettering Cancer Center ExperienceSigrid Carlsson, Nicole Benfante, Ricardo Alvim, Daniel D. Sjoberg, Andrew Vickers, Victor E. Reuter, Samson W. Fine, Hebert Alberto Vargas, Michal Wiseman, Maha Mamoor, Behfar Ehdaie, Vincent Laudone, Peter Scardino, James Eastham and Karim Touijer 2020;	2.5	
179	The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy. *World Journal of Urology*, **2021**, 1	4	4
178	Risk Stratification of Patients Candidate to Radical Prostatectomy Based on Clinical and Multiparametric Magnetic Resonance Imaging Parameters: Development and External Validation of Novel Risk Groups. *European Urology*, **2021**, 81, 193-193	10.2	9
177	Predictive value of preoperative neutrophil-to-lymphocyte ratio in localized prostate cancer: results from a surgical series at a high-volume institution. *Minerva Urology and Nephrology*, **2021**, 73, 481-488	2.3	2
176	Re: Marra et´al. PTransperineal freehand multiparametric MRI fusion targeted biopsies under local anaesthesia for prostate cancer diagnosis: a multicentre prospective study of 1014 casesP. *BJU International*, **2021**, 128, 523	5.6	1
175	Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy.. *European Urology*, **2021**,	10.2	3
174	Technical and Functional Validation of a Teleoperated Multirobots Platform for Minimally Invasive Surgery. *IEEE Transactions on Medical Robotics and Bionics*, **2020**, 2, 148-156	3.1	3
173	Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study. *European Urology Oncology*, **2020**, 4, 1001-1001	6.7	9
172	Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer. *European Urology*, **2020**, 77, 701-710	10.2	66
171	Preoperative frailty predicts adverse short-term postoperative outcomes in patients treated with radical prostatectomy. *Prostate Cancer and Prostatic Diseases*, **2020**, 23, 573-580	6.2	9
170	Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. *European Urology*, **2020**, 77, 614-627	10.2	52
169	Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. *European Urology*, **2020**, 78, 661-669	10.2	30
168	Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series. *European Urology*, **2020**, 78, 779-782	10.2	6
167	Re: Aurlie De Bruycker, Elise De Bleser, Karel Decaestecker, et al. Nodal Oligorecurrent Prostate Cancer: Anatomic Pattern of Possible Treatment Failure in Relation to Elective Surgical and Radiotherapy Treatment Templates. Eur Urol 2019;75:826-33: Nodal Recurrence of Prostate Cancer in Patients Treated with Radical Intent: Tailoring the Best Salvage Treatment. *European Urology*, **2020**, 77, e137	10.2	

166	Re: Ola Bratt, Erik Holmberg, Ove Andrén, et al. The Value of an Extensive Transrectal Repeat Biopsy with Anterior Sampling in Men on Active Surveillance for Low-risk Prostate Cancer: A Comparison from the Randomised Study of Active Monitoring in Sweden (SAMS). Eur Urol 2019;76:461-6. *European Urology*, **2020**, 77, e136	10.2	
165	Risk calculator for prediction of treatment-related urethroplasty failure in patients with penile urethral strictures. *International Urology and Nephrology*, **2020**, 52, 1079-1085	2.3	3
164	Re: Felix Preisser, Felix K.H. Chun, Raisa S. Pompe, et al. Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes. Eur Urol 2019;76:106-14. *European Urology*, **2020**, 77, e107	10.2	
163	Estimated Costs Associated With Radiation Therapy for Positive Surgical Margins During Radical Prostatectomy. *JAMA Network Open*, **2020**, 3, e201913	10.4	4
162	External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection. *European Urology*, **2020**, 78, 138-142	10.2	18
161	Re: Comparison of Initial Experience with Transrectal Magnetic Resonance Imaging Cognitive Guided Micro-Ultrasound Biopsies versus Established Transperineal Robotic Ultrasound Magnetic Resonance Imaging Fusion Biopsies for Prostate CancerO. R. Claros, R. R. Tourinho-Barbosa, A.	2.5	
160	Re: The Magnetic Resonance Imaging in Active Surveillance (MRIAS) Trial: Use of Baseline Multiparametric Magnetic Resonance Imaging and Saturation Biopsy to Reduce the Frequency of Surveillance Prostate BiopsiesA. Amin, M. J. Scheltema, R. Shnier, A. Blazevski, D. Moses, T. Cusick, A. Siriwardena, B. Yuen, P. J. van Leeuwen, A. M. Haynes, J. Matthews, P. Brenner, G. O'Neill, C. Yuen, W. Delprado, P. Stricker and J. Thompson 2020; 910-917. *Journal of Urology*, **2020**, 204, 843	2.5	0
159	Reply by Authors. *Journal of Urology*, **2020**, 204, 302	2.5	
158	Underestimation of Positron Emission Tomography/Computerized Tomography in Assessing Tumor Burden in Prostate Cancer Nodal Recurrence: Head-to-Head Comparison of Ga-PSMA and C-Choline in a Large, Multi-Institutional Series of Extended Salvage Lymph Node Dissections. *Journal of Urology*, **2020**, 204, 296-302	2.5	17
157	Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies. *European Urology*, **2020**, 77, 439-446	10.2	119
156	Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. *European Urology*, **2020**, 77, 636-643	10.2	48
155	Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection Following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 Trial. *European Urology*, **2020**, 77, 576-580	10.2	38
154	Relative Contribution of Sampling and Grading to the Quality of Prostate Biopsy: Results from a Single High-volume Institution. *European Urology Oncology*, **2020**, 3, 474-480	6.7	5
153	Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD). *European Urology Oncology*, **2020**, 4, 971-971	6.7	25
152	Re: Vasilis Stavrinides, Francesco Giganti, Bruce Trock, et al. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study. Eur Urol 2020;78:443-51. *European Urology*, **2020**, 78, e165	10.2	1
151	Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. *JAMA Oncology*, **2020**, 6, 1912-1920	13.4	15
150	Newly Diagnosed Oligometastatic Prostate Cancer: Current Controversies and Future Developments. *European Urology Oncology*, **2020**,	6.7	3
149	Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy. *European Urology Oncology*, **2020**, 3, 739-747	6.7	9

148	Focus on Internal Urethrotomy as Primary Treatment for Untreated Bulbar Urethral Strictures: Results from a Multivariable Analysis. *European Urology Focus*, **2020**, 6, 164-169	5.1	6
147	Performance of [Ga] Ga-PSMA 11 PET for detecting prostate cancer in the lymph nodes before salvage lymph node dissection: a systematic review and meta-analysis. *Prostate Cancer and Prostatic Diseases*, **2020**, 23, 1-10	6.2	18
146	There Is No Way to Avoid Systematic Prostate Biopsies in Addition to Multiparametric Magnetic Resonance Imaging Targeted Biopsies. *European Urology Oncology*, **2020**, 3, 112-118	6.7	23
145	The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging-targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Pathological Features in Prostate Cancer Patients Undergoing Radical Prostatectomy. *European Urology*, **2020**, 77, 733-741	10.2	38
144	Androgen deprivation therapy in men with node-positive prostate cancer treated with postoperative radiotherapy. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 204-209	2.8	5
143	Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations. *European Urology Focus*, **2020**, 6, 231-234	5.1	44
142	Therapeutic approaches for lymph node involvement in prostate, bladder and kidney cancer. *Expert Review of Anticancer Therapy*, **2019**, 19, 739-755	3.5	5
141	The Effect of Lymph Node Dissection in Metastatic Prostate Cancer Patients Treated with Radical Prostatectomy: A Contemporary Analysis of Survival and Early Postoperative Outcomes. *European Urology Oncology*, **2019**, 2, 541-548	6.7	17
140	Oncologic outcomes after robot-assisted versus open radical cystectomy: a systematic review and meta-analysis. *World Journal of Urology*, **2019**, 37, 1557-1570	4	10
139	The European Prostate Cancer Centres of Excellence: A Novel Proposal from the European Association of Urology Prostate Cancer Centre Consensus Meeting. *European Urology*, **2019**, 76, 179-186	10.2	10
138	Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study. *European Urology*, **2019**, 76, 443-449	10.2	8
137	The emerging role of PET-CT scan after radical prostatectomy: still a long way to go. *Lancet Oncology, The*, **2019**, 20, 1193-1195	21.7	3
136	EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). *European Urology*, **2019**, 76, 790-813	10.2	76
135	Oncologic outcomes in prostate cancer patients treated with robot-assisted radical prostatectomy: results from a single institution series with more than 10 years follow up. *Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology*, **2019**, 71, 38-46	4.4	10
134	The Impact of Experience on the Risk of Surgical Margins and Biochemical Recurrence after Robot-Assisted Radical Prostatectomy: A Learning Curve Study. *Journal of Urology*, **2019**, 202, 108-113	2.5	40
133	Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes. *European Urology*, **2019**, 75, 817-825	10.2	11
132	Study Protocol for the DETECTIVE Study: An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer. *European Urology*, **2019**, 75, 699-702	10.2	5
131	More Extensive Lymph Node Dissection Improves Survival Benefit of Radical Cystectomy in Metastatic Urothelial Carcinoma of the Bladder. *Clinical Genitourinary Cancer*, **2019**, 17, 105-113.e2	3.3	11

130	Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. *European Urology*, **2019**, 75, 967-987	10.2	128
129	A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies. *European Urology*, **2019**, 75, 506-514	10.2	91
128	Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis. *European Urology*, **2019**, 75, 176-183	10.2	60
127	PD-L1 Expression and CD8 T-cell Infiltrate are Associated with Clinical Progression in Patients with Node-positive Prostate Cancer. *European Urology Focus*, **2019**, 5, 192-196	5.1	60
126	Contemporary Trends and Survival Outcomes After Aborted Radical Prostatectomy in Lymph Node Metastatic Prostate Cancer Patients. *European Urology Focus*, **2019**, 5, 381-388	5.1	9
125	Are the Results of the Prostate Testing for Cancer and Treatment Trial Applicable to Contemporary Prostate Cancer Patients Treated with Radical Prostatectomy? Results from Two High-volume European Institutions. *European Urology Focus*, **2019**, 5, 545-549	5.1	2
124	A Head-to-head Comparison of Four Prognostic Models for Prediction of Lymph Node Invasion in African American and Caucasian Individuals. *European Urology Focus*, **2019**, 5, 449-456	5.1	8
123	Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. *Prostate*, **2018**, 78, 469-475	4.2	29
122	Reply to Mustafa Z. Temiz and Huseyin Besiroglu's Letter to the Editor re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. Eur Urol 2017;72:910-7. *European Urology*, **2018**, 73, e131-e132	10.2	
121	Survival benefit of local versus no local treatment for metastatic prostate cancer-Impact of baseline PSA and metastatic substages. *Prostate*, **2018**, 78, 753-757	4.2	21
120	External beam radiotherapy with or without androgen deprivation therapy in elderly patients with high metastatic risk prostate cancer. *Urologic Oncology: Seminars and Original Investigations*, **2018**, 36, 239.e9-239.e15	2.8	4
119	The Impact of Implementation of the European Association of Urology Guidelines Panel Recommendations on Reporting and Grading Complications on Perioperative Outcomes after Robot-assisted Radical Prostatectomy. *European Urology*, **2018**, 74, 4-7	10.2	29
118	More Extensive Lymph Node Dissection at Radical Prostatectomy is Associated with Improved Outcomes with Salvage Radiotherapy for Rising Prostate-specific Antigen After Surgery: A Long-term, Multi-institutional Analysis. *European Urology*, **2018**, 74, 134-137	10.2	8
117	Contemporary Management of Prostate Cancer Patients Suitable for Active Surveillance: A North American Population-based Study. *European Urology Focus*, **2018**, 4, 68-74	5.1	12
116	Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies. *European Urology*, **2018**, 73, 890-896	10.2	59
115	Identifying candidates for super-extended staging pelvic lymph node dissection among patients with high-risk prostate cancer. *BJU International*, **2018**, 121, 421-427	5.6	17
114	Radical prostatectomy or radiotherapy reduce prostate cancer mortality in elderly patients: a population-based propensity score adjusted analysis. *World Journal of Urology*, **2018**, 36, 7-13	4	17
113	Reply to Alan Dal Pra, Stephane Supiot and Pirus Ghadjar's Letter to the Editor re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. Eur Urol 2017;72:910-7. *European Urology*, **2018**, 73, e36-e37	10.2	

112	Location of Metastases in Contemporary Prostate Cancer Patients Affects Cancer-Specific Mortality. *Clinical Genitourinary Cancer*, **2018**, 16, 376-384.e1	3.3	17
111	Active Surveillance for Low-risk Prostate Cancer: The European Association of Urology Position in 2018. *European Urology*, **2018**, 74, 357-368	10.2	72
110	Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases. *European Urology Oncology*, **2018**, 1, 46-53	6.7	26
109	Is Robot-assisted Surgery Contraindicated in the Case of Partial Nephrectomy for Complex Tumours or Relevant Comorbidities? A Comparative Analysis of Morbidity, Renal Function, and Oncologic Outcomes. *European Urology Oncology*, **2018**, 1, 61-68	6.7	21
108	Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer. *European Urology Oncology*, **2018**, 1, 29-36	6.7	26
107	Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series. *European Urology*, **2018**, 73, 512-518	10.2	27
106	First North American validation and head-to-head comparison of four preoperative nomograms for prediction of lymph node invasion before radical prostatectomy. *BJU International*, **2018**, 121, 592-599	5.6	24
105	Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study. *International Urology and Nephrology*, **2018**, 50, 71-78	2.3	29
104	Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy. *European Urology*, **2018**, 73, 436-444	10.2	41
103	Reply to Riccardo Bertolo's Letter to the Editor re: Giorgio Gandaglia, Carlo Andrea Bravi, Paolo Dell'Oglio, et al. The Impact of Implementation of the European Association of Urology Guidelines Panel Recommendations on Reporting and Grading Complications on Perioperative Outcomes after Robot-assisted Radical Prostatectomy. Eur Urol 2018;74:4-7. *European Urology*, **2018**, 74, 116-e117	10.2	
102	How can we expand active surveillance criteria in patients with low- and intermediate-risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator. *BJU International*, **2018**, 122, 823-830	5.6	13
101	Not All Multiparametric Magnetic Resonance Imaging-targeted Biopsies Are Equal: The Impact of the Type of Approach and Operator Expertise on the Detection of Clinically Significant Prostate Cancer. *European Urology Oncology*, **2018**, 1, 120-128	6.7	37
100	Obstructive sleep apnea and Fuhrman grade in patients with clear cell renal cell carcinoma treated surgically. *World Journal of Urology*, **2017**, 35, 51-56	4	10
99	Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection in Patients with Locally-advanced Prostate Cancer. *European Urology*, **2017**, 71, 249-256	10.2	50
98	The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. *European Urology*, **2017**, 72, 84-109	10.2	203
97	Correlation Between Primary Hypospadias Repair and Subsequent Urethral Strictures in a Series of 408 Adult Patients. *European Urology Focus*, **2017**, 3, 287-292	5.1	9
96	Salvage Radiation Therapy for Increasing Prostate-Specific Antigen After Radical Prostatectomy: Who, When, and How?. *Journal of Clinical Oncology*, **2017**, 35, 469-470	2.2	3
95	Reply to Pascal Mouracade's Letter to the Editor re: Giorgio Gandaglia, Nicola Fossati, Armando Stabile, et al. Radical Prostatectomy in Men with Oligometastatic Prostate Cancer: Results of a Single-institution Series with Long-term Follow-up. Eur Urol 2017;72:289-92. Do the Data Violate Kaplan-Meier Assumptions?. *European Urology*, **2017**, 72, e31	10.2	2

94	Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer. *European Urology*, **2017**, 72, 632-640	10.2	93
93	Contemporary Incidence and Cancer Control Outcomes of Primary Neuroendocrine Prostate Cancer: A SEER Database Analysis. *Clinical Genitourinary Cancer*, **2017**, 15, e793-e800	3.3	30
92	Prediction of Competing Mortality for Decision-making Between Surgery or Observation in Elderly Patients With T1 Kidney Cancer. *Urology*, **2017**, 102, 130-137	1.6	9
91	Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. *European Urology*, **2017**, 72, 910-917	10.2	17
90	Are all grade group 4 prostate cancers created equal? Implications for the applicability of the novel grade grouping. *Urologic Oncology: Seminars and Original Investigations*, **2017**, 35, 461.e7-461.e14	2.8	14
89	An Explanatory Case on the Limitations of Lymph Node Staging in Recurrent Prostate Cancer. *Urology Case Reports*, **2017**, 12, 34-36	0.5	3
88	What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. *European Urology*, **2017**, 72, 250-266	10.2	218
87	Evaluating the effect of time from prostate cancer diagnosis to radical prostatectomy on cancer control: Can surgery be postponed safely?. *Urologic Oncology: Seminars and Original Investigations*, **2017**, 35, 150.e9-150.e15	2.8	29
86	New surgical approaches for clinically high-risk or metastatic prostate cancer. *Expert Review of Anticancer Therapy*, **2017**, 17, 1013-1031	3.5	5
85	When to Perform Preoperative Bone Scintigraphy for Kidney Cancer Staging: Indications for Preoperative Bone Scintigraphy. *Urology*, **2017**, 110, 114-120	1.6	5
84	Assessing the Impact of Surgeon Experience on Urinary Continence Recovery After Robot-Assisted Radical Prostatectomy: Results of Four High-Volume Surgeons. *Journal of Endourology*, **2017**, 31, 872-877	2.7	30
83	Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review. *European Urology*, **2017**, 72, 869-885	10.2	106
82	Hospitalization before surgery and subsequent risk of infective complications after radical cystectomy: A population-based analysis. *Urologic Oncology: Seminars and Original Investigations*, **2017**, 35, 659.e7-659.e12	2.8	
81	Salvage surgery for nodal recurrent prostate cancer. *Current Opinion in Urology*, **2017**, 27, 604-611	2.8	8
80	Long-term utility of adjuvant hormonal and radiation therapy for patients with seminal vesicle invasion at radical prostatectomy. *BJU International*, **2017**, 120, 69-75	5.6	8
79	The New Prostate Cancer Grading System Does Not Improve Prediction of Clinical Recurrence After Radical Prostatectomy: Results of a Large, Two-Center Validation Study. *Prostate*, **2017**, 77, 263-273	4.2	18
78	Testosterone Levels Correlate With Grade Group 5 Prostate Cancer: Another Step Toward Personalized Medicine. *Prostate*, **2017**, 77, 234-241	4.2	4
77	Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series. *European Urology*, **2017**, 71, 886-893	10.2	61

76	EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. *European Urology*, **2017**, 71, 618-629	10.2	1939
75	Radical Prostatectomy in Men with Oligometastatic Prostate Cancer: Results of a Single-institution Series with Long-term Follow-up. *European Urology*, **2017**, 72, 289-292	10.2	56
74	Robot-assisted Salvage Lymph Node Dissection for Clinically Recurrent Prostate Cancer. *European Urology*, **2017**, 72, 432-438	10.2	32
73	Robotic Assisted Simple Prostatectomy versus Holmium Laser Enucleation of the Prostate for Lower Urinary Tract Symptoms in Patients with Large Volume Prostate: A Comparative Analysis from a High Volume Center. *Journal of Urology*, **2017**, 197, 1108-1114	2.5	48
72	Early Postoperative Radiotherapy is Associated with Worse Functional Outcomes in Patients with Prostate Cancer. *Journal of Urology*, **2017**, 197, 669-675	2.5	39
71	Reply to Marc A. Bjurlin, Lee C. Zhao, and Michael D. Stifelman's Letter to the Editor Re: Nicol Maria Buffi, Giovanni Lughezzani, Rodolfo Hurle, et al. Robot-assisted Surgery for Benign Ureteral Strictures: Experience and Outcomes from Four Tertiary Care Institutions. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.07.022. *European Urology*, **2017**, 71, e92-e93	10.2	1
70	Incidence and Predictors of 30-Day Readmission After Robot-Assisted Radical Prostatectomy. *Clinical Genitourinary Cancer*, **2017**, 15, 67-71	3.3	12
69	Robot-assisted Surgery for Benign Ureteral Strictures: Experience and Outcomes from Four Tertiary Care Institutions. *European Urology*, **2017**, 71, 945-951	10.2	41
68	Pelvic lymph node dissection in prostate cancer: indications, extent and tailored approaches. *Urologia*, **2017**, 84, 9-19	1.2	20
67	Evaluation of positive surgical margins in patients undergoing robot-assisted and open radical prostatectomy according to preoperative risk groups. *Urologic Oncology: Seminars and Original Investigations*, **2016**, 34, 57.e1-7	2.8	20
66	Comparison of renal function detriments after local tumor ablation or partial nephrectomy for renal cell carcinoma. *World Journal of Urology*, **2016**, 34, 383-9	4	20
65	Prediction of Complications Following Partial Nephrectomy: Implications for Ablative Techniques Candidates. *European Urology*, **2016**, 69, 676-682	10.2	35
64	Salvage radiotherapy for patients with rising PSA. *Lancet Oncology, The*, **2016**, 17, e314-e315	21.7	
63	When to Perform Karyotype Analysis in Infertile Men? Validation of the European Association of Urology Guidelines with the Proposal of a New Predictive Model. *European Urology*, **2016**, 70, 920-923	10.2	30
62	Rationale for local treatment in the management of metastatic prostate cancer. *Current Opinion in Supportive and Palliative Care*, **2016**, 10, 266-72	2.6	5
61	Erectile Function Recovery After Nerve-Sparing Radical Prostatectomy for Prostate Cancer: Is Back to Baseline Status Enough for Patient Satisfaction?. *Journal of Sexual Medicine*, **2016**, 13, 669-78	1.1	9
60	Re: Stephen J. Freedland, Voleak Choeurng, Lauren Howard, et al. Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy. Eur Urol 2016;70:588-96: Testing the Utility of Genomic Scores in the Setting of Recurrent Prostate Cancer After Radical Prostatectomy: We Can Certainly Do Better. *European*	10.2	1
59	Comparison of oncologic outcomes between sarcomatoid and clear cell renal cell carcinoma. *World Journal of Urology*, **2016**, 34, 1429-36	4	12

58	Sociodemographic Disparities in the Nonoperative Management of Small Renal Masses. *Clinical Genitourinary Cancer*, **2016**, 14, e177-82	3.3	7
57	Incidence and Predictors of 30-Day Readmission in Patients Treated With Radical Cystectomy: A Single Center European Experience. *Clinical Genitourinary Cancer*, **2016**, 14, e341-6	3.3	9
56	Timing of blood transfusion and not ABO blood type is associated with survival in patients treated with radical cystectomy for nonmetastatic bladder cancer: Results from a single high-volume institution. *Urologic Oncology: Seminars and Original Investigations*, **2016**, 34, 256.e7-256.e13	2.8	15
55	Dose Escalation in Salvage Radiation Therapy and Urinary Toxicity: A Small Price to Pay for a Significant Prospective Benefit. *Journal of Clinical Oncology*, **2016**, 34, 1704-5	2.2	1
54	Assessment of the Rate of Adherence to International Guidelines for Androgen Deprivation Therapy with External-beam Radiation Therapy: A Population-based Study. *European Urology*, **2016**, 70, 429-35	10.2	9
53	The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients. *European Urology*, **2016**, 69, 1142-8	10.2	38
52	Predicting survival of men with recurrent prostate cancer after radical prostatectomy. *European Journal of Cancer*, **2016**, 54, 27-34	7.5	25
51	The Surgical Learning Curve for One-stage Anterior Urethroplasty: A Prospective Single-surgeon Study. *European Urology*, **2016**, 69, 686-690	10.2	32
50	Very long-term survival patterns of young patients treated with radical prostatectomy for high-risk prostate cancer. *Urologic Oncology: Seminars and Original Investigations*, **2016**, 34, 234.e13-9	2.8	13
49	Effect on postoperative survival of the status of distal ureteral margin: The necessity to achieve negative margins at the time of radical cystectomy. *Urologic Oncology: Seminars and Original Investigations*, **2016**, 34, 59.e15-22	2.8	14
48	Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy. *European Urology*, **2016**, 69, 728-733	10.2	78
47	The Authors Respond. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2016**, 14, 117-22	7.3	
46	Impact of stage migration and practice changes on high-risk prostate cancer: results from patients treated with radical prostatectomy over the last two decades. *BJU International*, **2016**, 117, 740-7	5.6	22
45	Population-based assessment of cancer-specific mortality after local tumour ablation or observation for kidney cancer: a competing risks analysis. *BJU International*, **2016**, 118, 541-6	5.6	11
44	Robot-Assisted Radical Cystectomy for Bladder Cancer in Octogenarians. *Journal of Endourology*, **2016**, 30, 792-8	2.7	21
43	Elective Nephron Sparing Surgery Decreases Other Cause Mortality Relative to Radical Nephrectomy Only in Specific Subgroups of Patients with Renal Cell Carcinoma. *Journal of Urology*, **2016**, 196, 1008-13	2.5	40
42	Reply from Authors re: Matthew C. Hayes, David J. Breen. Excision Versus Ablation in Renal Cancer: Optimising Outcome and Minimising Risk. Eur Urol 2016;69:683-4. *European Urology*, **2016**, 69, 684-685	10.2	
41	Intermediate-term cancer control outcomes in prostate cancer patients treated with robotic-assisted laparoscopic radical prostatectomy: a multi-institutional analysis. *World Journal of Urology*, **2016**, 34, 1357-66	4	7

40	Predicting the 5-Year Risk of Biochemical Relapse After Postprostatectomy Radiation Therapy in pT2, pN0 Patients With a Comprehensive Tumor Control Probability Model. *International Journal of Radiation Oncology Biology Physics*, **2016**, 96, 333-340	4	11
39	STAMPEDE trial and patients with non-metastatic prostate cancer. *Lancet, The*, **2016**, 388, 234-5	40	3
38	Timing of androgen-deprivation therapy for prostate cancer: still a long way to go. *Lancet Oncology, The*, **2016**, 17, e313	21.7	1
37	Clinical performance of serum isoform [-2]proPSA (p2PSA), and its derivatives %p2PSA and the Prostate Health Index, in men aged . *BJU International*, **2015**, 115, 913-20	5.6	25
36	Clinical performance of the Prostate Health Index (PHI) for the prediction of prostate cancer in obese men: data from the PROMEtheuS project, a multicentre European prospective study. *BJU International*, **2015**, 115, 537-45	5.6	20
35	Re: Editorial Comment on Clinical Performance of Serum Isoform (-2)proPSA (p2PSA) and its Derivatives, Namely %p2PSA and PHI (Prostate Health Index) in Men Younger than 60 Years of Age: Results from a Multicentric European Study: S. S. Taneja J Urol 2014;192:421. *Journal of Urology*,	2.5	4
34	Preoperative Prostate-specific Antigen Isoform p2PSA and Its Derivatives, %p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer: Results from a Multicentric European Prospective Study. *European Urology*, **2015**, 68, 132-8	10.2	56
33	Patterns of Clinical Recurrence of Node-positive Prostate Cancer and Impact on Long-term Survival. *European Urology*, **2015**, 68, 777-84	10.2	41
32	Margin, ischemia, and complications system to report perioperative outcomes of robotic partial nephrectomy: a European Multicenter Observational Study (EMOS project). *Urology*, **2015**, 85, 589-95	1.6	38
31	The Role of Radiotherapy After Radical Prostatectomy in Patients with Prostate Cancer. *Current Oncology Reports*, **2015**, 17, 53	6.3	6
30	Reply to C.G. Rusthoven et al. *Journal of Clinical Oncology*, **2015**, 33, 1989	2.2	1
29	Minimally Invasive Partial Nephrectomy Versus Laparoscopic Cryoablation for Patients Newly Diagnosed with a Single Small Renal Mass. *European Urology Focus*, **2015**, 1, 66-72	5.1	5
28	Long-term oncologic outcomes of laparoscopic renal cryoablation as primary treatment for small renal masses. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 22.e1-22.e9	2.8	38
27	Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study. *European Urology*, **2015**, 67, 3-6	10.2	95
26	Robot-assisted, single-site, dismembered pyeloplasty for ureteropelvic junction obstruction with the new da Vinci platform: a stage 2a study. *European Urology*, **2015**, 67, 151-156	10.2	31
25	MP87-13 IMPACT OF PRE-TREATMENT PSA LEVEL ON CANCER CONTROL AFTER EARLY SALVAGE RADIATION THERAPY POST RADICAL PROSTATECTOMY: NEED FOR PATIENT STRATIFICATION ACCORDING TO PROSTATE CANCER FEATURES. *Journal of Urology*, **2015**, 193,	2.5	1
24	The Impact of Insurance Status on Tumor Characteristics and Treatment Selection in Contemporary Patients With Prostate Cancer. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2015**, 13, 1351-8	7.3	15
23	Importance of prostate volume in the stratification of patients with intermediate-risk prostate cancer. *International Journal of Urology*, **2015**, 22, 555-61	2.3	11

22	Identification of pathologically favorable disease in intermediate-risk prostate cancer patients: Implications for active surveillance candidates selection. *Prostate*, **2015**, 75, 1484-91	4.2	19
21	Extended pelvic lymph node dissection in patients with prostate cancer previously treated with surgery for lower urinary tract symptoms. *BJU International*, **2015**, 116, 366-72	5.6	3
20	Does Radiotherapy Plus Androgen-Deprivation Therapy Represent the Best Treatment Approach in Elderly Patients With Locally Advanced Prostate Cancer?. *Journal of Clinical Oncology*, **2015**, 33, 2831-2	2.2	2
19	RE: Androgen Deprivation With or Without Radiation Therapy for Clinically Node-Positive Prostate Cancer. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	
18	Head-to-head comparison of lymph node density and number of positive lymph nodes in stratifying the outcome of patients with lymph node-positive prostate cancer submitted to radical prostatectomy and extended lymph node dissection. *Urologic Oncology: Seminars and Original Investigations*, **2014**, 32, 29.e21-8	2.8	20
17	Long-term followup and deterioration rate of anterior substitution urethroplasty. *Journal of Urology*, **2014**, 192, 808-13	2.5	83
16	The key role of time in predicting progression-free survival in patients with renal cell carcinoma treated with partial or radical nephrectomy: conditional survival analysis. *Urologic Oncology: Seminars and Original Investigations*, **2014**, 32, 43.e9-16	2.8	10
15	Relationship of chronic histologic prostatic inflammation in biopsy specimens with serum isoform [-2]proPSA (p2PSA), %p2PSA, and prostate health index in men with a total prostate-specific antigen of 4-10 ng/ml and normal digital rectal examination. *Urology*, **2014**, 83, 606-12	1.6	31
14	Prediction of early and late complications after oral mucosal graft harvesting: multivariable analysis from a cohort of 553 consecutive patients. *Journal of Urology*, **2014**, 191, 688-93	2.5	40
13	Clinical use of [-2]proPSA (p2PSA) and its derivatives (%p2PSA and Prostate Health Index) for the detection of prostate cancer: a review of the literature. *Korean Journal of Urology*, **2014**, 55, 436-45		19
12	Re: Systematic review and meta-analysis of perioperative and oncologic outcomes of laparoscopic cryoablation versus laparoscopic partial nephrectomy for the treatment of small renal tumors: T. Klatte, S. F. Shariat and M. Remzi. J Urol 2014; 191: 1209-1217. *Journal of Urology*, **2014**, 192, 1887-8	2.5	3
11	Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer. *Journal of Clinical Oncology*, **2014**, 32, 3939-47	2.2	184
10	Bladder cancer and urothelial impairment: the role of TRPV1 as potential drug target. *BioMed Research International*, **2014**, 2014, 987149	3	19
9	Predicting survival of patients with node-positive prostate cancer following multimodal treatment. *European Urology*, **2014**, 65, 554-62	10.2	61
8	Multicenter European external validation of a prostate health index-based nomogram for predicting prostate cancer at extended biopsy. *European Urology*, **2014**, 66, 906-12	10.2	65
7	Urethral lift for benign prostatic hyperplasia: a comprehensive review of the literature. *Current Urology Reports*, **2013**, 14, 620-7	2.9	11
6	Assessing the most accurate formula to predict the risk of lymph node metastases from prostate cancer in contemporary patients treated with radical prostatectomy and extended pelvic lymph node dissection. *Radiotherapy and Oncology*, **2013**, 109, 211-6	5.3	15
5	Presence of positive surgical margin in patients with organ-confined prostate cancer equals to extracapsular extension negative surgical margin. A plea for TNM staging system reclassification. *Urologic Oncology: Seminars and Original Investigations*, **2013**, 31, 1497-503	2.8	11

4	Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis. *European Urology*, **2013**, 63, 998-1008	10.2	88
3	Ventral oral mucosal onlay graft urethroplasty in nontraumatic bulbar urethral strictures: surgical technique and multivariable analysis of results in 214 patients. *European Urology*, **2013**, 64, 440-7	10.2	53
2	Spatial distribution of positive cores improves the selection of patients with low-risk prostate cancer as candidates for active surveillance. *BJU International*, **2013**, 112, E234-42	5.6	1
1	Optimizing postoperative sexual function after radical prostatectomy. *Therapeutic Advances in Urology*, **2012**, 4, 347-65	3.2	12